Table 1.
Clinical characteristics of patients and treatment modality of recurrent with primary liver cancer n (%)
| CK19- HCC (n = 49) | CK19+ HCC (n = 21) | cHCC-CC (n = 22) | ICC(n = 19) | P value | |
| Age (yr) | 0.43 | ||||
| < 45 | 11 (22.4) | 4 (19.0) | 4 (18.2) | 1 (5.3) | |
| ≥ 45 | 38 (77.6) | 17 (81.0) | 18 (81.8) | 18 (94.7) | |
| Gender | 0.014a | ||||
| Male | 41 (83.7) | 14 (66.7) | 18 (81.8) | 9 (47.4) | |
| Female | 8 (16.3) | 7 (33.3) | 4 (18.2) | 10 (52.6) | |
| Underlying liver disease | 0.004a | ||||
| None | 0 (0.0) | 0 (0.0) | 3 (13.6) | 12 (63.2) | |
| HBV | 38 (79.2) | 18 (85.7) | 17 (77.3) | 2 (10.5) | |
| HCV | 4 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Others | 6 (12.5) | 3 (14.3) | 2 (9.1) | 5 (26.3) | |
| Cirrhosis | 0.024a | ||||
| No | 22 (44.9) | 10 (47.6) | 10 (45.5) | 16 (84.2) | |
| Yes | 27 (55.1) | 11 (52.4) | 12 (54.5) | 3 (15.8) | |
| Tumor number | 0.313 | ||||
| Single | 41 (83.7) | 17 (81.0) | 16 (72.7) | 18 (94.7) | |
| Multiple | 8 (16.3) | 4 (19.0) | 6 (27.3) | 1 (5.3) | |
| Satellite nodule | 0.063 | ||||
| Absent | 43 (87.8) | 19 (90.5) | 15 (68.2) | 18 (94.7) | |
| Present | 6 (12.2) | 2 (9.5) | 7 (31.8) | 1 (5.3) | |
| Microvascular invasion | 0.836 | ||||
| Absent | 21 (42.9) | 10 (47.6) | 11 (55.0) | 9 (47.4) | |
| Present | 28 (57.1) | 11 (52.4) | 9 (45.0) | 10 (52.6) | |
| Macrovascular invasion | 0.119 | ||||
| Absent | 45 (91.8) | 17 (81.0) | 19 (95.0) | 14 (73.7) | |
| Present | 4 (8.2) | 4 (19.0) | 1 (5.0) | 5 (26.3) | |
| Lymph node metastasis | 0.086 | ||||
| Absent | 47 (95.9) | 20 (95.5) | 21 (95.5) | 15 (78.9) | |
| Present | 2 (4.1) | 1 (4.8) | 1 (4.5) | 4 (21.1) | |
| Distant metastasis | 0.521 | ||||
| Absent | 46 (93.9) | 21 (100) | 21 (95.5) | 17 (89.5) | |
| Present | 3 (6.1) | 0 (0.0) | 1 (4.5) | 2 (10.5) | |
| Differentiation | 0.301 | ||||
| E1, E2 or well, moderate | 15 (30.6) | 7 (33.3) | 9 (47.4) | 9 (52.9) | |
| E3, E4 or poorly | 34 (69.4) | 14 (66.7) | 10 (52.6) | 8 (47.1) | |
| Treatment modality | |||||
| Number of patience with recurrence | 19/49 (38.8) | 12/21 (57.1) | 15/22 (68.2) | 11/19 (57.9) | |
| Conservative treatment | 2/19 (10.5) | 1/12 (8.3) | 3/15 (20.0) | 8/11 (72.7) | |
| Transarterial chemoembolization | 15/19 (78.9) | 11/12 (91.7) | 12/15 (80.0) | 0/11 (0.0) | |
| Systemic chemotherapy | 0/19 (0.0) | 0/12 (0.0) | 0/15 (0.0) | 2/11 (3.5) | |
| Others | 2/19 (10.5) | 0/12 (0.0) | 0/15 (0.0) | 3/11 (5.3) |
a
P < 0.05 among 4 groups. CK19- HCC: Cytokeratin 19 negative hepatocellular carcinoma; CK19+ HCC: Cytokeratin 19 positive hepatocellular carcinoma; cHCC-CC: Combined hepatocellular carcinoma and cholangiocarcinoma; ICC: Intrahepatic cholangiocarcinoma; HBV: Hepatitis B virus; HCV: Hepatitis C virus.